Table 4.
Markers of Immune Activation and Senescence over 48 Weeks (Intent-to-Treat Population, Observed Values)
| |
DRV/r |
ATV/r |
||
|---|---|---|---|---|
| Parameter, mean % (SD) | BL | Week 48 | BL | Week 48 |
| CD4+ | ||||
| Naive (CCR7+/CD45RA+) | 47.9 (21.14) | 54.7 (19.55) | 38.9 (21.10) | 49.1 (20.91) |
| Central memory (CCR7+/CD45RA−) | 11.9 (8.45) | 14.2 (9.37) | 19.1 (14.49) | 15.0 (7.22) |
| Terminal effectors (CCR7−/CD45RA+) | 10.9 (5.50) | 9.4 (3.43) | 12.1 (8.78) | 11.4 (7.88) |
| Effector memory (CCR7−/CD45RA−) | 29.3 (18.85) | 21.7 (16.76) | 30.0 (12.03) | 24.5 (15.00) |
| CD38+/HLADR+ | 13.6 (7.10) | 8.5 (4.50) | 13.0 (10.82) | 10.9 (5.44) |
| Ki67+ | 1.9 (1.52) | 0.9 (0.86) | 1.6 (1.55) | 1.0 (0.97) |
| CD28−/CD57+ | 7.7 (12.75) | 1.7 (1.50) | 9.1 (14.72) | 3.5 (5.57) |
| CD8+a | ||||
| Naive (CCR7+/CD45RA+) | 13.6 (10.09) | 25.4 (15.63) | 15.4 (9.89) | 26.1 (12.33) |
| Central memory (CCR7+/CD45RA−) | 12.37 (12.43) | 8.7 (8.70) | 16.2 (10.32) | 8.5 (7.11) |
| Terminal effectors (CCR7−/CD45RA+) | 26.4 (14.91) | 27.2 (11.07) | 26.0 (16.67) | 33.9 (14.19) |
| Effector memory (CCR7−/CD45RA−) | 47.7 (14.85) | 38.7 (14.42) | 42.4 (14.85) | 31.4 (11.40) |
| CD38+/HLADR+ | 43.8 (17.75) | 19.4 (12.49) | 40.5 (17.51) | 22.2 (11.05) |
| Ki67+ | 2.8 (1.75) | 1.2 (0.75) | 2.3 (2.06) | 1.2 (0.78) |
| CD28−/CD57+ | 32.1 (11.81) | 19.6 (12.32) | 31.8 (15.02) | 22.8 (15.06) |
Sample size varies by time point and parameter.
a
CD8+ cell subpopulations were based on CD8+ percentages and were not directly measured.
SD, standard deviation; DRV/r, darunavir/ritonavir; ATV/r, atazanavir/ritonavir; BL, baseline; HLADR, human leukocyte antigen-DR.